查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1924717

核醫放射性藥物市場按類型、技術、放射性示蹤劑、最終用戶和應用分類－全球預測（2026-2032 年）

Nuclear Radiopharmaceutical Market by Type, Technology, Radiotracer, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，核醫放射性藥物市場價值將達到 64.4 億美元，到 2026 年將成長至 69 億美元，到 2032 年將達到 113 億美元，複合年成長率為 8.37%。

關鍵市場統計數據
基準年 2025 64.4億美元
預計年份：2026年 69億美元
預測年份 2032 113億美元
複合年成長率 (%) 8.37%

一份策略性入門指南，概述了影響核放射性藥物在整個醫療保健系統中應用的臨床作用、生產基礎設施和監管趨勢。

核放射性藥物融合了先進化學、精準醫學和診斷影像技術，使臨床醫生能夠可視化生理過程並以分子特異性治療疾病。本導論闡述了該領域的臨床和技術背景，闡明了放射性示蹤劑、放射性核種療法和輔助性遞送系統如何整合到現代治療方案中。此外，本導論還概述了不斷發展的生產方法和法規結構如何影響其在醫院、影像中心和研究實驗室的應用。

治療診斷學、分散式同位素生產、自動化和監管現代化等融合趨勢將如何重塑價值鍊和臨床應用？

核子醫學領域正經歷一場變革浪潮，這場變革正在重塑臨床實務、供應鏈和經營模式。診療治療診斷學） ——一種將診斷與標靶放射性核治療相結合的綜合方法——在促進核醫學醫師、腫瘤醫師和放射性藥物藥劑師之間的跨學科合作方面發揮著核心作用。這種轉變強調伴隨診斷，將患者與治療方法相匹配，從而加速了精準醫療的進程，並提升了放射性藥物研發的臨床提案。

評估關稅政策變化對核醫放射性藥物生態系中供應鏈、生產決策和採購行為的連鎖反應。

調整關稅制度的政策變化會透過增加投入成本、改變競爭格局和加強策略在地化，對放射性藥物生態系統產生連鎖反應。如果設備、原料或前驅物同位素的進口關稅提高，製造商必須評估是否自行承擔成本、將其轉嫁給醫療服務提供者，或是重組供應鏈。每一種選擇都會產生臨床和商業性影響，因為穩定的價格和可靠的供應對於接受常規診斷和時間敏感型治療的患者至關重要。

整合細分洞察，將治療方式、放射性示蹤劑特性、最終用戶需求和臨床應用優先順序連結起來，從而指南策略選擇。

細分市場層面的趨勢分析揭示了不同的需求促進因素、臨床路徑和營運要求，從而指南產品開發和市場推廣策略。依應用領域（診斷/治療）分析放射性物質的使用情況，顯示出供應鍊和監管要求的顯著差異：診斷流程包括PET和SPECT模式，其中PET的生產主要圍繞F-18示踪劑，而SPECT通常使用Technetium-99m。治療應用主要以碘-131用於甲狀腺疾病和鎦-177用於胜肽受體放射性核素治療主導，每種應用在劑量、安全性和分銷方面都有其獨特的考量。

美洲、歐洲、中東和非洲以及亞太地區的區域基礎設施、監管差異和臨床應用模式將如何決定戰略進入和擴張選擇。

區域趨勢影響著生產能力、監管方式、臨床應用模式和夥伴關係機會，因此需要製定具有地理針對性的策略。在美洲，完善的臨床基礎設施和強大的專業設施網路支持著先進PET示踪劑和放射性核素療法的快速應用。報銷系統和集中式臨床試驗網路促進了新型治療診斷學的應用，同時也對臨床效用和成本效益的驗證提出了更高的要求。

主要企業的定位和合作趨勢揭示了製造規模、日益複雜的監管以及整合服務模式如何驅動競爭優勢。

公司層面的發展趨勢反映了專業化、垂直整合和協作模式的結合，這些模式共同塑造了當前的競爭格局。大型醫療設備製造商和放射性藥物開發商正在投資於整契約位素生產、自動化合成模組和伴隨診斷的解決方案，以縮短臨床應用時間並提高不同試驗點之間的一致性。同時，專業的合約研發生產機構 (CDMO) 和發生器製造商在幫助小規模創新企業無需大量前期投資即可擴大生產規模方面發揮著至關重要的作用。

產業領導者可以立即採取哪些具體策略和營運步驟，以增強韌性、加速應用並獲取放射性藥物領域的臨床價值

為了充分利用不斷變化的放射性藥物市場環境，企業領導者應採取一系列切實可行的措施，兼顧短期韌性和長期成長。優先考慮供應來源多元化，並在經濟條件允許的情況下投資本地生產能力，可以降低貿易中斷和關稅帶來的風險。與合約研發生產機構 (CDMO) 和區域製造商建立策略聯盟，既能加快市場准入，又能降低資本密集度。實施模組化、自動化的合成和包裝平台，可以提高多個生產基地的生產效率一致性，並降低營運風險。

本報告採用透明的混合方法，結合專家訪談、技術文獻綜合和多方資訊來源檢驗，以確保研究結果具有可操作性和檢驗。

本報告的研究結合了質性專家對話、系統性文獻檢驗和三角驗證法，以確保證據基礎的穩健性和平衡性。關鍵投入包括與臨床醫生、生產專家和供應鏈經理進行結構化訪談，以了解實際營運中的限制因素、臨床應用促進因素和採購考量。此外，還與放射化學和法規事務專家進行了技術諮詢，以檢驗關於生產方法、穩定性挑戰和合規性要求的假設。

對匯聚的科學、營運和政策力量進行簡明扼要、綜合分析，這些力量將決定哪些組織能夠在推動核放射性藥物醫學方面取得成功。

核醫放射性藥物正處於關鍵的轉折點，科學創新、生產現代化和政策演變在此交匯融合，創造了巨大的臨床和商業性機會。治療診斷學的興起、生產技術的多元化以及對自動化和監管清晰度的日益重視，共同擴大了診斷示踪劑和標靶治療的實際應用範圍。整合生產製造、臨床證據產生和策略夥伴關係的相關人員，將更有能力把技術可能性轉化為對病人的實際影響。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 核醫放射性藥物市場（按類型分類）

  • 診斷
  • 治療

9. 按技術分類的核醫放射性藥物市場

  • PET
  • SPECT

第10章 核醫放射性藥物市場（依放射性示蹤劑分類）

  • F-18
  • 碘-131
  • 鎦-177
  • Tc-99M

第11章 核醫放射性藥物市場（依最終用戶分類）

  • 醫院
  • 診斷影像中心
  • 研究所

第12章 核醫放射性藥物市場（依應用領域分類）

  • 循環系統
  • 神經病學
  • 腫瘤學

第13章 核醫放射性藥物市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 核醫放射性藥物市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國核醫放射性藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國核醫放射性藥物市場

第17章 中國核醫放射性藥物市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Advanced Accelerator Applications SA
  • Bayer AG
  • Bracco Imaging SpA
  • BWXT Medical Ltd.
  • Cardinal Health, Inc.
  • Clarity Pharmaceuticals Ltd.
  • Curium Pharma SAS
  • Eckert & Ziegler SE
  • Eli Lilly and Company
  • GE HealthCare Technologies Inc.
  • ITM Isotope Technologies Munich SE
  • Jubilant Pharmova Limited
  • Lantheus Holdings, Inc.
  • NorthStar Medical Radioisotopes, LLC
  • Novartis AG
  • RayzeBio, Inc.
  • Shanghai United Imaging Healthcare Co., Ltd.
  • Siemens Healthineers AG
  • SOFIE Biosciences, Inc.
  • Telix Pharmaceuticals Limited
Product Code: MRR-7A380DA7C44A

The Nuclear Radiopharmaceutical Market was valued at USD 6.44 billion in 2025 and is projected to grow to USD 6.90 billion in 2026, with a CAGR of 8.37%, reaching USD 11.30 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.44 billion
Estimated Year [2026] USD 6.90 billion
Forecast Year [2032] USD 11.30 billion
CAGR (%) 8.37%

A strategic primer that frames the clinical roles, production enablers, and regulatory vectors shaping nuclear radiopharmaceutical adoption across healthcare systems

Nuclear radiopharmaceuticals occupy a distinct intersection of advanced chemistry, precision medicine, and diagnostic imaging, enabling clinicians to visualize physiological processes and treat disease with molecular specificity. This introduction establishes the clinical and technological context for the dossier, clarifying how radiotracers, radionuclide therapies, and supporting delivery systems integrate into contemporary care pathways. It also outlines how evolving production modalities and regulatory frameworks influence adoption across hospitals, imaging centers, and research institutes.

Radiopharmaceuticals serve two primary clinical roles: diagnostic imaging, which includes positron emission tomography and single-photon emission computed tomography applications, and therapeutic interventions that deliver targeted radioisotopes to diseased tissues. Diagnostic radiotracers such as F-18 derivatives provide high-resolution metabolic and molecular information, while technetium-99m-based agents remain essential for a broad range of routine imaging. On the therapeutic side, iodine-131 continues to underpin thyroid treatments, and lutetium-177-labeled agents are establishing new paradigms in peptide receptor radionuclide therapy.

Advances in production-spanning cyclotron-based synthesis of short-lived PET isotopes, generator systems for rapid technetium-99m access, and improved radiolabeling automation-are key enablers of broader clinical deployment. Meanwhile, regulatory emphasis on GMP-compliant manufacturing, dose standardization, and patient safety drives capital investments and process innovation. Together, these technical and regulatory vectors set the stage for strategic decisions by manufacturers, clinical operators, and investors seeking to participate in a field that is rapidly moving from niche specialty use toward more integrated roles in oncology, cardiology, and neurology.

How converging trends in theranostics, decentralized isotope production, automation, and regulatory modernization are redefining value chains and clinical adoption

The nuclear radiopharmaceutical arena is undergoing transformative shifts that are remaking clinical practice, supply chains, and commercial models. Theranostics-an integrated approach combining diagnostics and targeted radionuclide therapy-has emerged as a rallying point, fostering cross-disciplinary collaboration between nuclear medicine physicians, oncologists, and radiopharmacists. This shift emphasizes companion diagnostics that match patients to therapies, accelerating precision medicine pathways and elevating the clinical value proposition of radiopharmaceutical development.

Concurrently, decentralization of isotope production is gaining momentum. Investments in regional cyclotron installations and compact accelerator platforms are reducing reliance on distant centralized suppliers and high-risk distribution routes. This trend enhances local resilience and shortens time-to-patient for short-lived PET isotopes, while generator-based solutions continue to offer reliable access to technetium-99m in settings without advanced infrastructure. Such production plurality drives competitiveness and encourages novel business models that pair manufacturing services with clinical support.

On the technology front, automation of radiochemistry workflows and the standardization of kits and cassettes reduce variability and lower barriers to clinical adoption. Image quantification improvements, coupled with artificial intelligence-enabled interpretation, are improving diagnostic precision and enabling more objective endpoints in clinical trials. Regulatory pathways are also evolving to accommodate the unique characteristics of radiopharmaceuticals, with authorities increasingly recognizing the need for tailored guidance on manufacturing controls, stability testing, and clinical endpoints. These combined dynamics are reshaping value chains, creating new entrants, and prompting legacy players to rethink partnerships, distribution strategies, and investment priorities.

Assessing how changes in tariff policy can ripple across supply chains, production decisions, and procurement behavior in the nuclear radiopharmaceutical ecosystem

Policy shifts that adjust tariff regimes can cascade through the radiopharmaceutical ecosystem by increasing input costs, altering competitive dynamics, and incentivizing strategic localization. When import duties rise on equipment, raw materials, or precursor isotopes, manufacturers must evaluate whether to absorb costs, pass them to healthcare providers, or reconfigure supply chains. Each choice carries clinical and commercial implications, because stable pricing and reliable supply are essential for routine diagnostic schedules and for patients receiving time-sensitive therapeutic doses.

Higher tariffs can catalyze nearshoring decisions, prompting investments in domestic cyclotron capacity, generator assembly facilities, and local radiopharmacy services. Such investments mitigate exposure to cross-border trade friction but require significant capital, skilled personnel, and regulatory approvals. In the interim, increased tariffs can compress margins for external suppliers and distributors, incentivizing consolidation or vertical integration among manufacturers and healthcare systems seeking to secure availability and control costs.

Tariff-driven cost pressures also affect instrument manufacturers and suppliers of consumables, potentially slowing procurement of imaging devices or automated synthesis modules in cost-sensitive settings. As a result, imaging centers and hospitals may prioritize technologies with the most favorable total cost of ownership or favor suppliers with local support networks. Over time, differential tariff impacts can shift competitive advantages between domestic and foreign producers, influencing partner selection, contract negotiations, and long-term procurement strategies.

Importantly, the interaction between tariffs and regulatory policies magnifies the effect of trade measures. Regulatory incentives for domestic production, such as streamlined facility approvals or procurement preferences, can reinforce the localization trend. Conversely, exemptions for critical medical supplies or diplomatic arrangements may alleviate immediate pressures. Stakeholders should therefore monitor both trade policy developments and corresponding regulatory responses, assess supply chain vulnerabilities, and model scenarios that prioritize treatment continuity and patient safety while preserving commercial viability.

Integrated segmentation insights that connect modality, radiotracer specifics, end-user requirements, and clinical application priorities to inform strategic choices

Segment-level dynamics reveal differentiated demand drivers, clinical pathways, and operational requirements that should inform product development and go-to-market strategies. Based on type, activity splits between diagnostic and therapeutic uses show distinct supply chain and regulatory needs: diagnostic workflows encompass PET and SPECT modalities where PET production frequently revolves around F-18 tracers and SPECT commonly leverages technetium-99m; therapeutic applications are led by iodine-131 for thyroid conditions and lutetium-177 for peptide receptor radionuclide therapy, each with unique dosing, safety, and distribution considerations.

Viewed through the lens of technology, PET and SPECT platforms remain foundational, with PET centering on F-18 production pathways that demand cyclotron access and rapid distribution, while SPECT utilizes Tc-99m that benefits from generator availability and kit-based radiochemistry. End users span hospitals, imaging centers, and research institutes, and each setting imposes different procurement cycles, staffing expertise, and regulatory compliance burdens that affect the selection of tracers, automation levels, and service agreements.

Radiotracer segmentation highlights the centrality of F-18, I-131, Lu-177, and Tc-99m. F-18 applications are often exemplified by FDG kits and protocols optimized for metabolic imaging; I-131 remains indispensable for thyroid therapeutics with well-established dosing regimens; Lu-177 is increasingly associated with peptide receptor radionuclide therapy programs that require coordinated patient selection pathways and specialized handling; and Tc-99m maintains broad utility where generators and kits enable flexible, on-site radiopharmacy operations.

Application-based segmentation across cardiovascular, neurology, and oncology underscores clinical prioritization. Oncology leads adoption of theranostic pairings and targeted therapies, neurology benefits from tracers that characterize neurodegenerative disease biology, and cardiovascular imaging relies on robust protocols for perfusion and viability assessment. Integrating these segmentation perspectives helps stakeholders align manufacturing scale, distribution models, and clinical support services with distinct operational realities across diagnostic and therapeutic domains.

How regional infrastructure, regulatory diversity, and clinical adoption patterns across the Americas, Europe Middle East & Africa, and Asia-Pacific determine strategic entry and scaling choices

Regional dynamics shape production capacity, regulatory approaches, clinical adoption patterns, and partnership opportunities in ways that demand geographically informed strategies. In the Americas, established clinical infrastructures and a strong network of specialized centers support rapid uptake of advanced PET tracers and radionuclide therapies; reimbursement mechanisms and centralized trial networks often facilitate the introduction of new theranostics but can also create high expectations for demonstration of clinical utility and cost-effectiveness.

In Europe, the Middle East & Africa, regulatory heterogeneity, disparate infrastructure maturity, and diverse healthcare financing models produce a patchwork of demand signals. Western European centers with robust nuclear medicine programs drive early adoption of complex radiotherapeutics, while segments within the broader region face constraints that favor generator-based solutions and kits. Strategic partnerships, regional manufacturing hubs, and technology transfer programs can accelerate access where infrastructure gaps exist, but stakeholders must navigate varied approval pathways and procurement norms.

Asia-Pacific presents a rapidly evolving landscape where investments in cyclotron facilities, growing clinical trial activity, and expanding healthcare coverage underpin rising interest in both diagnostics and therapeutics. National priorities to build domestic capacity and secure supply chains are fostering localized production initiatives, while the scale and diversity of healthcare systems across the region create opportunities for tiered product offerings and flexible business models. Across all regions, aligning commercialization plans with local regulatory expectations, clinician training priorities, and logistical realities remains essential for successful market entry and sustained adoption.

Key corporate positioning and partnership trends revealing how manufacturing scale, regulatory sophistication, and integrated service models drive competitive advantage

Company-level dynamics reflect a mix of specialization, vertical integration, and collaborative models that collectively define the competitive terrain. Leading device manufacturers and radiopharmaceutical developers are investing in integrated solutions that combine isotope production, automated synthesis modules, and companion diagnostics to shorten clinical implementation timelines and improve consistency across sites. At the same time, specialized contract development and manufacturing organizations (CDMOs) and generator producers play a pivotal role in enabling smaller innovators to scale without large upfront capital investments.

Partnerships between clinical research organizations, academic centers, and industry are a common route to de-risk early-stage development and validate therapeutic hypotheses. Licensing agreements and co-development partnerships allow companies to combine proprietary ligands, radiochemistry know-how, and clinical expertise to accelerate registration pathways. Meanwhile, strategic acquisitions are used to secure manufacturing capacity, expand geographic reach, and internalize critical supply chain capabilities.

Companies that prioritize regulatory intelligence, invest in robust GMP-compliant manufacturing, and maintain responsive technical support networks enjoy stronger adoption in clinical settings that require high reliability. Differentiation increasingly arises from the ability to offer end-to-end solutions-spanning tracer availability, quality control, clinical training, and reimbursement support-rather than from single product features alone. For investors and corporate strategists, evaluating potential partners requires careful assessment of manufacturing redundancy, intellectual property position, and demonstrated clinical outcomes to ensure alignment with long-term therapeutic and diagnostic roadmaps.

Concrete strategic and operational moves that industry leaders can implement immediately to build resilience, accelerate adoption, and capture clinical value in radiopharmaceuticals

Leaders aiming to capitalize on the evolving radiopharmaceutical environment should pursue a set of pragmatic actions that balance near-term resilience with long-term growth. Prioritizing diversification of supply sources and investing in localized production capacity where economically justified can reduce exposure to trade disruptions and tariffs, while strategic alliances with CDMOs or regional manufacturers can accelerate market entry with lower capital intensity. Implementing modular, automated synthesis and packaging platforms will improve throughput consistency and reduce operational risk across multiple sites.

Clinically, organizations should invest in evidence generation that demonstrates comparative effectiveness and patient-centered outcomes for new radiotracers and therapies, enabling stronger reimbursement positioning. Building multidisciplinary clinician engagement programs that include nuclear medicine, oncology, cardiology, and neurology stakeholders will support appropriate patient selection and protocol standardization. From a commercial standpoint, packaging service bundles that combine tracer supply, technical training, and regulatory support can differentiate offerings and foster long-term customer relationships.

Operationally, strengthening cold chain logistics, ensuring redundant supply pathways, and maintaining robust quality management systems will protect continuity of care. Decision-makers should also establish clear scenario planning processes to model the impact of trade policy changes, technological disruptions, or shifts in clinical guidelines, and use those scenarios to inform capital allocation and partnership choices. Taken together, these actions create a resilient platform from which organizations can scale clinical programs and capture the value emerging from theranostic innovations.

A transparent mixed-methods approach combining expert interviews, technical literature synthesis, and cross-source triangulation to ensure actionable and validated insights

The research behind this report combines qualitative expert engagement with systematic document review and triangulation to ensure a balanced and defensible evidence base. Primary inputs include structured interviews with clinicians, manufacturing experts, and supply chain managers to capture real-world operational constraints, clinical adoption drivers, and procurement considerations. These conversations are complemented by technical consultations with radiochemistry specialists and regulatory affairs professionals to validate assumptions about production methods, stability challenges, and compliance requirements.

Secondary research involved reviewing peer-reviewed literature, regulatory guidance documents, clinical trial registries, and publicly available company disclosures to map technology capabilities, clinical trial outcomes, and product approvals. Where available, white papers and technical notes on cyclotron operations, generator technology, and automated synthesis modules were used to clarify production characteristics and quality control practices. Information from logistics and healthcare infrastructure studies helped contextualize regional differences in deployment feasibility.

Data synthesis employed a triangulation approach that reconciled insights from interviews, technical documents, and clinical literature to identify consistent patterns and surface divergent viewpoints. Sensitivity analyses on operational scenarios were used to stress-test strategic implications, and iterative validation sessions with subject matter experts refined the final narrative. Throughout, methodological rigor emphasized transparency in source provenance, clarity about assumptions, and attention to clinical relevance to ensure the findings support practical decision-making.

A concise synthesis of the convergent scientific, operational, and policy forces that will determine which organizations succeed in advancing nuclear radiopharmaceutical care

Nuclear radiopharmaceuticals stand at a pivotal juncture where scientific innovation, production modernization, and evolving policy intersect to create significant clinical and commercial opportunities. The ascendancy of theranostics, the diversification of production technologies, and the increasing emphasis on automation and regulatory clarity are collectively expanding the practical reach of both diagnostic tracers and targeted therapies. Stakeholders that align manufacturing, clinical evidence generation, and strategic partnerships will be best positioned to translate technical promise into patient impact.

At the same time, trade policy shifts and regional infrastructure disparities introduce complexity that requires proactive planning. By prioritizing supply chain resilience, targeted investments in localized capabilities where appropriate, and robust clinical engagement to demonstrate value, organizations can navigate uncertainty while accelerating adoption. Ultimately, success will depend on the ability to integrate technical excellence with pragmatic operational strategies that ensure consistent access to high-quality radiopharmaceuticals for patients across diverse healthcare settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Nuclear Radiopharmaceutical Market, by Type

  • 8.1. Diagnostic
  • 8.2. Therapeutic

9. Nuclear Radiopharmaceutical Market, by Technology

  • 9.1. Pet
  • 9.2. Spect

10. Nuclear Radiopharmaceutical Market, by Radiotracer

  • 10.1. F-18
  • 10.2. I-131
  • 10.3. Lu-177
  • 10.4. Tc-99M

11. Nuclear Radiopharmaceutical Market, by End User

  • 11.1. Hospitals
  • 11.2. Imaging Centers
  • 11.3. Research Institutes

12. Nuclear Radiopharmaceutical Market, by Application

  • 12.1. Cardiovascular
  • 12.2. Neurology
  • 12.3. Oncology

13. Nuclear Radiopharmaceutical Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Nuclear Radiopharmaceutical Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Nuclear Radiopharmaceutical Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Nuclear Radiopharmaceutical Market

17. China Nuclear Radiopharmaceutical Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Advanced Accelerator Applications S.A.
  • 18.6. Bayer AG
  • 18.7. Bracco Imaging S.p.A.
  • 18.8. BWXT Medical Ltd.
  • 18.9. Cardinal Health, Inc.
  • 18.10. Clarity Pharmaceuticals Ltd.
  • 18.11. Curium Pharma SAS
  • 18.12. Eckert & Ziegler SE
  • 18.13. Eli Lilly and Company
  • 18.14. GE HealthCare Technologies Inc.
  • 18.15. ITM Isotope Technologies Munich SE
  • 18.16. Jubilant Pharmova Limited
  • 18.17. Lantheus Holdings, Inc.
  • 18.18. NorthStar Medical Radioisotopes, LLC
  • 18.19. Novartis AG
  • 18.20. RayzeBio, Inc.
  • 18.21. Shanghai United Imaging Healthcare Co., Ltd.
  • 18.22. Siemens Healthineers AG
  • 18.23. SOFIE Biosciences, Inc.
  • 18.24. Telix Pharmaceuticals Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY RADIOTRACER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY DIAGNOSTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY PET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY PET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY PET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY SPECT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY SPECT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY SPECT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY RADIOTRACER, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY F-18, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY F-18, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY F-18, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY I-131, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY I-131, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY I-131, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY LU-177, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY LU-177, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY LU-177, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TC-99M, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TC-99M, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TC-99M, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY IMAGING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY IMAGING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY IMAGING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY RADIOTRACER, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY RADIOTRACER, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY RADIOTRACER, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY RADIOTRACER, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY RADIOTRACER, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY RADIOTRACER, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY RADIOTRACER, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY RADIOTRACER, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY RADIOTRACER, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. GCC NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GCC NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. GCC NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 108. GCC NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY RADIOTRACER, 2018-2032 (USD MILLION)
  • TABLE 109. GCC NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. GCC NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY RADIOTRACER, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY RADIOTRACER, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. G7 NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. G7 NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. G7 NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. G7 NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY RADIOTRACER, 2018-2032 (USD MILLION)
  • TABLE 127. G7 NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. G7 NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. NATO NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. NATO NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. NATO NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 132. NATO NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY RADIOTRACER, 2018-2032 (USD MILLION)
  • TABLE 133. NATO NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. NATO NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY RADIOTRACER, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. CHINA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY RADIOTRACER, 2018-2032 (USD MILLION)
  • TABLE 146. CHINA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)